


Elecoglipron
CAS 3011682-49-5
MFC48H46F2N10O5 MW880.9 g/mol
3-[1-[2-[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-7-[(4S)-2,2-dimethyloxan-4-yl]indolizin-3-yl]cyclopropyl]-4H-1,2,4-oxadiazol-5-one
- 1,2,4-Oxadiazol-5(2H)-one, 3-[1-[2-[[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-7-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-3-indolizinyl]cyclopropyl]-
- 3-(1-(2-((S)-2-(3-cyclopropyl-4-fluorophenyl)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-7-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)indolizin-3-yl)cyclopropyl)-1,2,4-oxadiazol-5(4H)-one
- 3-[1-[2-[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-7-[(4S)-2,2-dimethyloxan-4-yl]indolizin-3-yl]cyclopropyl]-4H-1,2,4-oxadiazol-5-one

glucagon-like peptide 1 (GLP-1) receptor agonist, AZD 5004, ECC 5004, G94JJ74N5Y
Elecoglipron (AZD5004 / ECC-5004) is a glucagon-like peptide 1 (GLP-1) receptor agonist. In vitro, AZD5004/ECC5004 binds the human GLP-1 receptor with high affinity (IC₅₀ ~ 2.4 nM), drives G s-coupled cAMP signaling with low-nanomolar potency (EC₅₀ ~ 2–6 nM in HEK293/β-cell cAMP and GSIS assays), shows partial agonism in some cell systems without detectable β-arrestin recruitment or receptor internalization, and potentiates glucose-stimulated insulin secretion (EC₅₀ ~ 5.9 nM). In in vivo non-human primate studies, oral dosing produced robust pharmacodynamic effects — insulin secretion and glucose clearance with estimated EC₅₀ ~ 0.022 nM — and dose-dependent reductions in body-weight gain over long-term dosing, consistent with GLP-1-mediated metabolic effects
PAT
US-11584751-B1
https://patentscope.wipo.int/search/en/detail.jsf?docId=US392022131&_cid=P22-MOWB0S-70559-1
PAT
US-12037339-B2



AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

References
- Substituted imidazoles as GLP-1 receptor agonistsPublication Number: US-12037339-B2Priority Date: 2020-07-20Grant Date: 2024-07-16
- Substituted imidazoles as GLP-1 receptor agonistsPublication Number: US-11584751-B1Priority Date: 2020-07-20Grant Date: 2023-02-21
//////elecoglipron, anax labs, glucagon-like peptide 1 (GLP-1) receptor agonist, AZD 5004, ECC 5004, G94JJ74N5Y
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
